These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19007764)

  • 21. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
    Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5.
    Lin SX; Shi R; Qiu W; Azzi A; Zhu DW; Dabbagh HA; Zhou M
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):38-46. PubMed ID: 16480815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
    Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
    Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
    Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells.
    Matsunaga T; Arakaki M; Kamiya T; Endo S; El-Kabbani O; Hara A
    Chem Biol Interact; 2009 Sep; 181(1):52-60. PubMed ID: 19442656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
    Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
    J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
    Li C; Zhao Y; Zheng X; Zhang H; Zhang L; Chen Y; Li Q; Hu X
    Chem Biol Interact; 2016 Jun; 253():60-5. PubMed ID: 27163852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
    Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
    Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
    Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of homogeneous recombinant rat ovarian 20alpha-hydroxysteroid dehydrogenase: fluorescent properties and inhibition profile.
    Ma H; Penning TM
    Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):853-9. PubMed ID: 10417353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
    Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
    J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Winkler JD; Penning TM
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1464-8. PubMed ID: 21277203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
    Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
    Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
    Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.
    Skarydova L; Hofman J; Chlebek J; Havrankova J; Kosanova K; Skarka A; Hostalkova A; Plucha T; Cahlikova L; Wsol V
    J Steroid Biochem Mol Biol; 2014 Sep; 143():250-8. PubMed ID: 24769118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
    Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
    PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
    Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.